|1.||Abou-Issa, Hussein: 1 article (05/2005)|
|2.||Nieves, Nirca J: 1 article (05/2005)|
|3.||Highland, Margaret A: 1 article (05/2005)|
|4.||Stonerock, Laura A: 1 article (05/2005)|
|5.||Walker, Joel R: 1 article (05/2005)|
|6.||Clagett-Dame, Margaret: 1 article (05/2005)|
|7.||Alshafie, Galal A: 1 article (05/2005)|
|8.||Curley, Robert W: 1 article (05/2005)|
09/01/1997 - "Tumor regression occurred in 75% of the rats fed 2 mmol/Kg diet of 4-HPROG. "
05/01/2005 - "Previous studies from our laboratory suggest that 4-HPROG, the O-glucuronide derivative of 4-HPR, has improved mammary cancer chemopreventive/ antitumor activities as well as reduced toxicity, as compared to 4-HPR. "
03/01/1999 - "Tumor latency was 15% longer in rats fed 2 mmol/kg diet of 4-HPRCG as compared to 4-HPROG. "
03/01/1996 - "Although the stable C-linked analogs bound poorly to the nuclear retinoic acid receptors, many showed more potency than the less stable 4-HPROG in inhibiting tumor incidence and multiplicity in vivo. "
03/01/1999 - "At 80 days post DMBA intubation the control rats had an average of 1.43 tumors/rat compared to 0.71 and 0.36 tumors/rat in the 4-HPROG and 4-HPRCG respectively. "
|2.||Retinoic Acid Receptors (Retinoic Acid Receptor)
|4.||Vitamin A (Retinol)